For many hospitals and large institutions, OEM buybacks became the default way to handle high-value equipment.
The appeal is clear: speed, simplicity, and a transaction tied directly to new procurement.
In many situations, that structure still works.
But when buybacks become automatic rather than intentional, institutions may give up flexibility, transparency, and negotiating leverage without realizing it.
The real question isn’t which method is easier. It’s which approach gives the institution more control.
Most OEM buybacks do not provide unrestricted cash. They offer credit tied to future purchases with the same manufacturer.
That creates two important limitations:
That may be acceptable in some cases. But it reduces purchasing freedom and limits market transparency.
Open-market resale introduces competitive price discovery.
When equipment is exposed to a broader buyer pool, institutions gain:
In many cases, resale markets produce higher returns than rebate structures.
Importantly, testing the resale market does not eliminate buyback options.
Institutions can:
Exploring the market first preserves options rather than limiting them.
Even when institutions plan to accept a buyback, outside offers provide leverage.
Documented third-party interest can:
Without external price signals, rebate terms often go unchallenged.
Introducing market feedback strengthens institutional negotiating power.
Different asset categories perform differently in secondary markets.
High-end medical equipment, lab devices, IT assets, and furniture should not all follow the same disposition pathway.
Strong governance means defining criteria — not relying on habit.
OEM buybacks will continue to play an important role in equipment turnover.
But automatic defaults can quietly reduce:
Testing resale markets before committing to rebates — or running both in parallel — introduces structure without adding unnecessary complexity.
In asset disposition, optionality creates control. And control is what good governance requires.